Novartis Investigative Site

Bad Berka 99438

0 studies enrolling now · 7 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer, Advanced NET of GI Origin, Advanced NET of Lung Origin, Advanced Neuroendocrine Tumors of Pancreatic Origin, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Symptomatic Refractory Resistant Carcinoid Disease

Studies at this site

• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib — Completed
• This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. — Stopped early
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) — Completed
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges — Completed
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors — Completed
• Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease — Completed